Literature DB >> 11599793

Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions.

S Günther1, O Kühle, D Rehder, G N Odaibo, D O Olaleye, P Emmerich, J ter Meulen, H Schmitz.   

Abstract

It is not known whether the small 11-kDa Z protein of Lassa virus is immunogenic during human Lassa virus infection. To obtain evidence for the existence of an antibody response and to test the suitability of these antibodies for serosurveys, sera from Lassa fever endemic regions (Guinea and Nigeria, n = 75) were tested for co-reactivity to Z protein and nucleoprotein (NP). Sera from a non-endemic region (Uganda, n = 50) served as a specificity control. Z protein and NP were expressed in Escherichia coli, affinity-purified, and used as antigen in Western blot. Indirect immunofluorescence (IIF) with Lassa virus-infected cells was performed for comparison. Due to high unspecific reactivity of the African sera, Western blot testing was performed with a 1:1,000 serum dilution. Under these conditions, none of the control sera but 12% of the sera from endemic regions co-reacted with both Z protein and NP. Reactivity to Z protein was significantly associated with NP reactivity (P < 10(-6)). NP and Z protein-specific antibodies were co-detected in 33% of the IIF-positive sera and in 5% of the IIF-negative sera (P = 0.001). These data provide evidence for appearance of antibodies to Z protein and NP following Lassa virus infection. A recombinant blot for detection of both antibody specificities seems to be specific but less sensitive than IIF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599793     DOI: 10.1007/s004300100061

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  9 in total

1.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

3.  Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.

Authors:  Junki Maruyama; Elizabeth J Mateer; John T Manning; Rachel Sattler; Alexey V Seregin; Natalya Bukreyeva; Frank R Jones; Joseph P Balint; Elizabeth S Gabitzsch; Cheng Huang; Slobodan Paessler
Journal:  Vaccine       Date:  2019-09-24       Impact factor: 3.641

4.  Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever.

Authors:  Masayuki Saijo; Marie-Claude Georges-Courbot; Philippe Marianneau; Victor Romanowski; Shuetsu Fukushi; Tetsuya Mizutani; Alain-Jean Georges; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

5.  Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report.

Authors:  Luis M Branco; Matt L Boisen; Kristian G Andersen; Jessica N Grove; Lina M Moses; Ivana J Muncy; Lee A Henderson; John S Schieffellin; James E Robinson; James J Bangura; Donald S Grant; Vanessa N Raabe; Mbalu Fonnie; Eleina M Zaitsev; Pardis C Sabeti; Robert F Garry
Journal:  Virol J       Date:  2011-08-15       Impact factor: 4.099

Review 6.  Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.

Authors:  Hannah L Murphy; Hinh Ly
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 7.  Pathogenesis of Lassa fever.

Authors:  Nadezhda E Yun; David H Walker
Journal:  Viruses       Date:  2012-10-09       Impact factor: 5.048

Review 8.  Immune responses and Lassa virus infection.

Authors:  Marion Russier; Delphine Pannetier; Sylvain Baize
Journal:  Viruses       Date:  2012-11-05       Impact factor: 5.048

Review 9.  Current research for a vaccine against Lassa hemorrhagic fever virus.

Authors:  Bryce M Warner; David Safronetz; Derek R Stein
Journal:  Drug Des Devel Ther       Date:  2018-08-14       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.